Anti-Osteopontin [2A1] Antibody

This mouse IgG2a monoclonal antibody (clone AK1G4) was generated against purified recombinant human Osteopontin (OPN) and is specific for the C-terminal region of human OPN (epitope: aa 13-16).

Osteopontin (OPN, also designated Bone Sialoprotein 1, Urinary Stone Protein, spp-1, eta-1, nephropontin, uropontin) is a phosphoglycoprotein synthesized in a variety of tissues and cells. It was originally identified as a bone matrix protein and subsequently as a cytokine produced by various immune and transformed cell lines. OPN is a biomarker for various types of cancers and inflammatory diseases. Excessive or dysregulated OPN expression has been linked to the pathogenesis of both autoimmune disorders such as multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, atherosclerosis and other inflammatory diseases including cardiovascular disease, chronic obstructive pulmonary disease, inflammatory bowel disease, liver disease and asthma.

From the laboratory of David T. Denhardt, PhD, Rutgers University .

The Investigator's Annexe Part of The Investigator's Annexe program.

Catalog Number Product DataSheet Size AVAILABILITY Price Qty
Anti-Osteopontin [2A1] Antibody, 50ug
50ug In stock
Regular Price:$256.00
On Sale:

Product Type: Antibody
Antigen: Osteopontin (OPN) protein
Accession ID: P10451
Isotype: IgG1, kappa
Clonality: Monoclonal
Clone Name: 2A1
Reactivity: Human and mouse
Immunogen: recombinant histidine-tagged human OPN (prepared in E. coli and purified on a nickel column)
Species Immunized: Mouse
Epitope: aa 206-208
Purification Method: Protein G
Buffer: 0.1M Sodium Phosphate, pH 7.4, 0.15M NaCl, 0.05% (w/v) Sodium Azide
Tested Applications: WB, ELISA, IP, IF, IHC
Storage: -20C
Shipped: Cold packs


mAb recognition of OPN in Western Blots

OPN Figure

A: Western blots showing antibody recognition of murine OPN. Conditioned media (10 ul/lane) from various cell lines or 50 ng of recombinant murine OPN (GST-mOPN) were separated on 12% SDS–PAGE gels and transferred to PVDF membranes. The membranes were then cut into strips which were blotted with monoclonal antibodies at 1 ug/ml or polyclonal control (shown above each lane). 275-3-2: ras-transformed murine fibroblast cell line. 275: non-transformed murine fibroblast 3T3 cell line. MC3T3E1: preosteoblast cell line induced to differentiate for 12 days. B: Western blot of human urine detected with anti-OPN mAbs. Urine was collected and dialyzed extensively against 0.1M NaCl before approximately tenfold concentration with Centriprep spin columns. Five microliters of the concentrated, dialyzed urine was assayed via SDS–PAGE and Western blotting with mAbs at 1 ug/ml. Polyclonal antibody LF124 (kindly provided by Dr. Larry Fisher, NIH) and polyclonal anti-OPN (recombinant) mouse serum were used as controls.

Adapted from: Wang KX, et al. J Immunol. 2009 Feb 15;182(4):2485-91.

From the laboratory of David T. Denhardt, PhD, Rutgers University .
  1. Kazanecki CC, Kowalski AJ, Ding T, Rittling SR, Denhardt DT. Characterization of anti-osteopontin monoclonal antibodies: Binding sensitivity to post-translational modifications. J Cell Biochem. 2007 Nov 1;102(4):925-35.
  2. Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev. 2008 Oct-Dec;19(5-6):333-45.
  3. Christensen B, Klaning E, Nielsen MS, Andersen MH, Sorensen ES. C-terminal Modification of Osteopontin Inhibits Interaction with the ?V?3-Integrin. J Biol Chem. 2012 February 3; 287(6): 3788–3797.
  4. Wang KX, Shi YF, Ron Y, Kazanecki CC, Denhardt DT. Plasma osteopontin modulates chronic restraint stress-induced thymus atrophy by regulating stress hormones: inhibition by an anti-osteopontin monoclonal antibody. J Immunol. 2009 Feb 15;182(4):2485-91.
  5. Nagao M, Feinstein TN, Ezura Y, Hayata T, Notomi T, Saita Y, Hanyu R, Hemmi H, Izu Y, Takeda S, Wang K, Rittling S, Nakamoto T, Kaneko K, Kurosawa H, Karsenty G, Denhardt DT, Vilardaga JP, Noda M. Sympathetic control of bone mass regulated by osteopontin. Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):17767-72.

If you publish research with this product, please let us know so we can cite your paper.